.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Cantor Fitzgerald
Johnson and Johnson
Chubb
Deloitte
Healthtrust
McKesson
Fish and Richardson
UBS
Federal Trade Commission

Generated: June 28, 2017

DrugPatentWatch Database Preview

Claims for Patent: 6,753,006

« Back to Dashboard

Claims for Patent: 6,753,006

Title: Paclitaxel-containing formulations
Abstract:In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of a pharmaceutically active agent, wherein the agent is associated with a polymeric biocompatible material.
Inventor(s): Desai; Neil P. (Los Angeles, CA), Soon-Shiong; Patrick (Los Angeles, CA)
Assignee: American BioScience, Inc. (Santa Monica, CA)
Application Number:09/629,501
Patent Claims: 1. A unit dosage form of paclitaxel comprising a sealed vial containing a quantity of non-crystalline, cremophor-free paclitaxel suitable for administration to a human over an administration period no greater than about 3 hours, wherein said quantity is sufficient to deliver a dose between 30-1000 mg/m.sup.2 over said administration period.

2. A unit dosage form according to claim 1, wherein said dose is between 50-300 mg/m.sup.2.

3. A unit dosage form according to claim 1, wherein said dose is between 175-700 mg/m.sup.2.

4. A unit dosage form of paclitaxel comprising a sealed vial containing a quantity of non-crystalline, cremophor-free paclitaxel suitable for administration to a human with a treatment cycle less than about 3 weeks, wherein said quantity is sufficient to deliver a dose between 30-1000 mg/m.sup.2.

5. A unit dosage form according to claim 4, wherein said dose is between 50-300 mg/m.sup.2.

6. A unit dosage form according to claim 4, wherein said dose is between 175-700 mg/m.sup.2.

7. A unit dosage form of paclitaxel comprising an article of manufacture, wherein said article comprises a sealed vial containing a quantity of non-crystalline, cremophor-free paclitaxel suitable for administration to a human over an administration period no greater than about 3 hours, wherein said quantity is sufficient to deliver a dose between 30-1000 mg/m.sup.2 over said administration period.

8. A unit dosage form according to claim 7, wherein said dose is between 50-300 mg/m.sup.2.

9. A unit dosage form according to claim 7, wherein said dose is between 175-700 mg/m.sup.2.

10. A unit dosage form according to claim 7, wherein said administration is accomplished as a single dose.

11. A stable, sterile, nonpyrogenic, nonaqueous formulation of paclitaxel wherein the formulation contains a sufficient quantity of non-crystalline, cremophor-free paclitaxel to allow systemic administration at a dose in the range of about 30 mg/m.sup.2 to about 1000 mg/m.sup.2.

12. A formulation according to claim 11, wherein said dose is between 175-700 mg/m.sup.2.

13. A formulation according to claim 11, wherein said dose is between 50-300 mg/m.sup.2.

14. A formulation according to claim 11, wherein said administration is accomplished as a single dose.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Covington
Novartis
Cipla
Cantor Fitzgerald
Express Scripts
Deloitte
Accenture
McKinsey
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot